anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We aimed to identify caregivers' opinions on the outcome measures that matter in clinical trials in individuals with Dravet syndrome (DS). We conducted a prospective European multicenter study based on an 11 closed questions survey developed by the French reference center for rare epilepsies and DS patients' advocacy groups. Items included questions on seizures and daily life outcomes that a clinical trial on a therapy for individuals with DS should target. Statistical analyses were performed to evaluate the impact of the country of residence and of the patients' age. The survey was answered by 153 caregivers (68%: France, 28%: Germany, and 24%: Italy) off individuals with DS. Individuals with DS included 86 males (mean age of 11.4 [interquartile: 7-20.4] years). Families ranked as important almost all the items proposed. However, items related to daily life had the highest rank in all three countries compared to items about seizures (P = 0.02). Increase in individuals' age was associated with a higher age at diagnosis (ρ = 0.26, P = 0.02), and a lower impact of seizure duration (ρ = -0.25, P = 0.005) and on the need of hospital referral (ρ = -0.26, P = 0.005). These data can help tailor patient-centered outcome measures in future clinical and real-life trials for DS.
University of Texas Southwestern PGY-1 and PGY-2 Obstetrics and Gynecology residents will be scheduled to complete a 4-week gynecology rotation at Parkland Memorial Hospital. After completing the pre-survey, trainees will be randomized into either the control or experimental group (video coached group) stratified by PGY (Post-Graduate Year) level. Minimum group sample sizes of 9 and 9 to achieve 90% power to detect a difference of 5.0 in a design with 3 repeated measurements having a Simple covariance structure when the standard deviation is 5.4 and the alpha level is 0.05. The control group will be video recorded performing three laparoscopic salpingectomy procedures as scheduled during the 4-week block. The control group will not participate in video coaching sessions. The experimental group will be video recorded performing three laparoscopic salpingectomy procedures as scheduled during the block. After the first and second laparoscopic salpingectomy, the experimental group of residents will review their video recording and receive a video coaching session by a minimally invasive gynecologic surgery (MIGS) attending physician prior to the next surgery. All three video recordings for each participant (control and experimental group) will be graded using Global Operative Assessment of Laparoscopic Skills (GOALS) and Objective Structured Assessment of Laparoscopic Salpingectomy (OSA-LS) criteria by two attending physicians not involved in the surgeries or coaching. Each surgery will be blinded to the group allocation and the week definition. Participants will not be given the assessment score and the score will not affect evaluations. After the third laparoscopic salpingectomy, trainees will fill out a post-course survey to determine if the video-based coaching course improved their proficiency and confidence in laparoscopic gynecologic surgery. They will also watch their own laparoscopic salpingectomy video recording and self-grade their skills using the GOALS and OSA-LS criteria that will be provided in the post-survey.
BACKGROUND: Increasing attention has been raised on the surgical option for lung cancer patients aged ≥75 years, however, few studies have focused on whether uniportal video-assisted thoracoscopic surgery (VATS) is safe and feasible for these patients. This study aimed to evaluate short-term results of uniportal versus three-port VATS for the treatment of lung cancer patients aged ≥75 years.
METHODS: We retrospectively evaluated 582 lung cancer patients (≥75 years) who underwent uniportal or three-port VATS from August 2007 to August 2021 based on the Western China Lung Cancer Database. The baseline and perioperative outcomes between uniportal and three-port VATS were compared in the whole cohort (WC) and the patients undergoing lobectomy (lobectomy cohort, LC) respectively. Propensity score matching (PSM) was used to minimize confounding bias between the uniportal and three-port cohorts in WC and LC.
RESULTS: Intraoperative blood loss was significantly less in the uniportal than three-port LC (50 mL vs. 83 mL, P = 0.007) before PSM and relatively less in the uniportal than three-port LC (50 mL vs. 83 mL, P = 0.05) after PSM. Significantly more lymph nodes harvested (13 vs. 9, P = 0.007) were found in the uniportal than three-port LC after PSM. In addition, in WC and LC, there were no significant differences between uniportal and three-port cohorts in terms of operation time, the rate of conversion to thoracotomy during surgery, nodal treatments (dissection or sampling or not), the overall number of lymph node stations dissected, postoperative complications, volume and duration of postoperative thoracic drainage, hospital stay after operation and hospitalization expenses before and after PSM (P > 0.05).
CONCLUSIONS: There were no significant differences in short-term outcomes between uniportal and three-port VATS for lung cancer patients (≥75 years), except relatively less intraoperative blood loss (P < 0.05 before PSM and P = 0.05 after PSM) and significantly more lymph nodes harvested (P < 0.05 after PSM) were found in uniportal LC. It is reasonable to indicate that uniportal VATS is a safe, feasible and effective operation procedure for lung cancer patients aged ≥75 years.
INTRODUCTION: The association between magnesium level and progression to acute kidney disease (AKD) in acute kidney injury (AKI) patients was not well studied. With AKI transition to AKD, the burden of the disease on mortality, morbidity, and healthcare costs increases. Serum magnesium disturbances are linked with a decline in renal function and increased risk of death in CKD and hemodialysis patients. This study aims to assess the significance of magnesium derangements as a risk factor for the progression of AKI to AKD in critically ill patients.
METHODS: This study was conducted among patients with AKI admitted to the intensive care units at Mayo Clinic from 2007 to 2017. Serum magnesium at AKI onset was categorized into five groups of <1.7, 1.7-1.9, 1.9-2.1, 2.1-2.3, and ≥2.3 mg/dL, with 1.9-2.1 mg/dL as the reference group. AKD was defined as AKI that persisted >7 days following the AKI onset. Logistic regression was used to evaluate the association between magnesium and AKD.
RESULTS: Among 20,198 critically ill patients with AKI, the mean age was 66 ± 16 years, and 57% were male. The mean serum magnesium at AKI onset was 1.9 ± 0.4 mg/dL. The overall incidence of AKD was 31.4%. The association between serum magnesium and AKD followed a U-shaped pattern. In multivariable analysis, serum magnesium levels were associated with increased risk of AKD with the odds ratio of 1.17 (95% CI: 1.07-1.29), 1.13 (95% CI: 1.01-1.26), and 1.65 (95% CI: 1.48-1.84) when magnesium levels were <1.7, 2.1-2.3, and ≥2.3 mg/dL, respectively.
CONCLUSION: Among patients with AKI, magnesium level derangement was an independent risk for AKD in critically ill AKI patients. Monitoring serum magnesium and proper correction in critically ill patients with AKI should be considered an AKD preventive intervention in future trials.
The invention is a new strain of bacteria Paenibacillus curdlanolyticus MP-I, deposited at the Instytut Biotechnologii Przemyslu Rolno-Spozywczego in Warsaw, Poland under the no. KKP 2017p. This strain is particularly well- suited for the production of mutanase. The invention also concerns the application of a glucan of fungal origin as inductor of mutanase for human- targeted preparations, in particular as a component of dental hygiene products. The glucan comes from fungi. A method was also invented to produce mutanase based on the new strain and the glucan of fungal origin. The invention also covers an enzymatic preparation containing mutanase.
The invention relates to a cold scream for softening and tendering skin. A formula of the cold scream comprises the following raw materials in parts by weight: 3.0 parts of spermaceti, 6.0 parts of olive oil, 4.0 parts of lanolin, 0.6 part of borax, 32.0 parts of white oil, 0.3 part of essence, 0.2 part of petitgrain oil, a proper amount of preservative and antioxidant, 8.0 parts of beewax and refined water which is added until the total weight part is 100. The cold scream is used for moisturizing and protecting the skin under the synergy of the usage amount and physicochemical properties of all the raw materials. The pH value of the cold scream approaches to that of a human body, so that the cold cream is nonirritating to skin. After the cold cream is used, an obvious comfortable and soft feeling is obtained and an obvious moisturizing effect is realized. The cold cream has obvious effects of softening and tendering the skin and enhancing the adhesive force of face powder.
Obsessive-compulsive disorder (OCD) is a relatively common psychiatric condition with an estimated lifetime prevalence of 2-3 % of the general population. It is generally characterized by a chronic course leading to a profound impairment in psychosocial functioning and to a marked deterioration in quality of life. Today, the well-established efficacy of antidepressants, acting preferentially by blocking serotonin reuptake, in addition to psychological treatments, have considerably changed the poor prognosis of the illness. However, both conventional therapeutic approaches failed to substantially alleviate obsessive-compulsive symptoms in 20-30% of cases. Deep brain stimulation, as a reversible and adjustable surgical procedure, has recently been introduced in the field of OCD, primarily targeting either the ventral striatum (VS) or the subthalamic nucleus (STN) and leading to an approximately 40% or greater reduction in clinical symptom intensity from baseline levels in severely chronic and resistant forms of OCD. These promising findings lead to propose a comparison of the efficacy, safety and tolerability of DBS choosing either the VS or STN as brain target by conducting a multicenter, parallel-group, randomized, single-blind trial over a 13-month follow-up period. For this purpose, a total population of 28 OCD patients who meet the currently used operational criteria for defining therapeutic resistance will be recruited. The surgical procedure will consist in the implantation of stimulation electrodes with four contacts on each lead, which are stereotactically and bilaterally implanted into the targeted brain structure under local anesthesia. Per-operative, single-unit electrophysiological recordings of the neuronal activity will be performed using five parallel microelectrodes and serving as guide for the implantation of both definitive electrodes. They will be connected to a battery powered pulse-generating device five days later under general anesthesia. Thereafter, psychiatric assessments including both the Y-BOCS ("Yale-Brow Obsessive-compulsive scale") and PI ("Padua Inventory") for measuring OCD symptom severity, the BAS ("Brief Anxiety Scale"), MADRS ("Montgomery and Asberg Depression rating Scale") and HAD ("Hospital Anxiety and Depression Scale") for determining anxiety and/or depressive symptom intensity, and the CGI ("Clinical Global Impression") rating scales for evaluating global symptom severity and treatment response will be performed every 3 months beyond the one-month postoperative free-stimulation period. This will be coupled with a large battery of neuropsychological tests exploring all executive functions in combination with precise medical records of side effects for appreciating safety/tolerability of DBS. A cost-effectiveness analysis, as a formal method of comparing DBS and classical therapeutic strategies with regard to their respective resource utilization (costs) and outcomes (effectiveness) will also be carried out. Therefore, the present study may contribute to highlight the special interest of DBS, as an effective, safe, well-tolerated and cost-relevant surgical approach for the management of resistant OCD.
The invention discloses the effect of a novel mutant human cytokine and fusion protein thereof on treatment of metabolic diseases. The human cytokine with mutant expression in mammalian cells is protein as shown in SEQ ID No. 3 in a sequence table. According to the invention, a wild human cytokine gene is subjected to mutation and N-terminal reconstruction, and the fusion protein contains a human cytokine mutant and the Fc segment (CH2-CH3) of human IgG4. The mammalian cell-expressed recombinant cytokine fusion protein has good activity in reducing blood sugar; in particular, the fusion protein has the advantages of high stability, long half life, etc.; and the fusion protein can well control fluctuation of blood sugar and stably maintain blood sugar at a normal level within 24 h.
PURPOSE:The titled food capable of reducing blood viscosity causing symptom such as suppressing effect on metabolite of arachidonic acid, or hyperlipemia, etc., comprising an extract obtained by extracting Ganodema licidum with hot water to give an extract, extracting further it with an oxygen-containing organic solvent, as an essential component. CONSTITUTION:Ganodema licidum is dried, cut in a sliced or minced state, extracted with warm water, the extracted solution is filtered, to give an extract with hot water. The dried powder of the extract with hot water is extracted with an oxygen-containing organic solvent (e.g., ketone solvent such as acetone, ether solvent such as ethyl ether, etc., alcoholic solvent such as methyl alcohol, etc.), the extractive operations are repeated twice, and a solvent-soluble component is filtered and separated. The filtrate is concentrated, evaporated to dryness to give an extract of Ganodema licidum. A food containing it as an essential compound is prepared to improve hypertension, hyperlipemia, hepatitis, diabetes, unidentified complaint syndrome, etc. This food is in the form of powder or refreshing drink, etc. wherein one can take 3,000-9,000mg of it.
The present invention relates to identification of a compound which inhibits the enzyme NMPRTase and glioma cancer cell growth and further used for glioma therapy. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes nicotinamide phosphoribosyltransferase (NMPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. PBEF1 transcript and protein levels have been shown to be elevated in glioblastoma and a chemical inhibitor of NMPRTase has been shown to specifically inhibit cancer cells. Here a structure based drug discovery approach has been reported with an aim to develop novel inhibitors for glioblastoma therapy. Present invention relates to virtual screening using docking of ligands from a large library of 13,000 compounds against NMPRTase as the macromolecular target resulting in short listing of 34 possible ligands, of which six were tested experimentally, using the NMPRTase enzyme inhibition assay and further with the glioma cell viability assays. Of these, two compounds were found to be significantly efficacious in inhibiting the conversion of nicotinamide to NAD, and out of which one compound, 3-amino-2-benzyl-7-nitro-4-(2-quinolyl-)-1,2-dihydroisoquinolin-1-one, was found to inhibit the growth of a PBEF1 over expressing glioma derived cell line U87 also.
Increased numbers of circulating stem cells and physical activity are both associated with improved health in older persons. This pilot study is the initial step in developing a collaborative, translational research project investigating whether physical activity may in part exert a positive influence on aging via the mobilization of stem cells. The specific aim of this pilot project is to collect preliminary data to explore the relationship between physical activity and stem cell populations found in the blood and to determine the variance in the number of circulating stem cells. We hypothesize that stem cell decrease with age, but that persons who are more physically active will have a higher number of stem cells in the blood. A maximum of 40 persons will be recruited to participate. Persons are eligible to participate if they are age 60 or older, haven't been hospitalized recently, do not have an immunologic or blood disease, do not have an infection, and are not undergoing chemotherapy. Subjects will have 2 visits to the UNMC Clinical Research Center (CRC). The first assessment will include an evaluation of health, physical activity and lifestyle via questionnaires. Height, weight and abdominal girth will be measured, and blood will be drawn for immune and stem cell assessment. Subjects will be given a pedometer and accelerometer to wear daily for 7 days. Subjects will return to the CRC for a second visit at which the pedometer and accelerometer will be returned and blood will be drawn. Stem cell and immune assays will be repeated to evaluate the variability of these measures over time. The correlation between stem cell numbers and physical activity will be analyzed. The data will be used to perform sample size calculations for the development of future studies.
PURPOSE: A composition containing a gene which suppresses ion channel expression is provided to effectively prevent inlet of intracellular calcium ion without side effects. CONSTITUTION: A composition for treating erectile failure contains a gene which suppresses the expression of ion channel relating to ion inlet at a tissue. The tissue is corpus cavernosum penis smooth muscle. The ion is calcium ion(Ca^2). The ion channel is TRPC6 ion channel. The gene is a dominant negative form gene.
Even low doses of aspirin can inhibit platelet function leading to an increase in bleeding time. This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. Aspirin is contraindicated in patients with hemophilia.

Aspirin administered pre-operatively may prolong the bleeding time.

Patients who consume three or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin.
The invention discloses a porcine epidemic diarrhea virus variant and an inactivated vaccine prepared from the same and application of the porcine epidemic diarrhea virus variant. The invention firstly discloses a separated porcine epidemic diarrhea virus variant PEDV-HB strain, and the microorganism preservation number is as follows: CGMCC No. 14889. The invention further discloses application of the PEDV-HB strain in preparation of a vaccine for preventing porcine epidemic diarrhea. The invention also discloses a vaccine composition for preventing porcine epidemic diarrhea, which comprises the following components: a prophylactically effective amount of the inactivated porcine epidemic diarrhea virus variant PEDV-HB strain and a pharmaceutically acceptable adjuvant. The inactivated vaccine prepared by the porcine epidemic diarrhea virus variant PEDV-HB strain has good safety and good immune effect, and can better prevent and control the porcine epidemic diarrhea. The PEDV-HB strain of the porcine epidemic diarrhea virus separated by the invention can be used as a candidate vaccine strain for preventing and controlling the porcine epidemic diarrhea disease.
The EGRI, a multivariate risk index that combines seven variables associated with DTI, was evaluated in all patients during the pre-anaesthesia visit. The results were reported in the clinical chart. All tracheal intubations in obese patients needing surgery were routinely performed using GVL. The intubations were performed or assisted by five board-certified anaesthesiologists who had prior experience with at least 20 GVL intubations, as well as at least two years of experience with anaesthesia in obese patients. In cases where the GVL intubation was performed by anaesthesiologists that were in training, the GVL expert was actively advising the operator during all of the intubating procedures. The standard equipment included a GVL with blade number three to five and an orotracheal hockey stick tube with a malleable single-use stylet (Fr 14, Intubating Stylet, DEAS). The standard anaesthesia induction started with 3-5 minutes of pre-oxygenation using 5 cm H2O PEEP in a 30° head-up position, as well as induction with fentanyl 3 μg kg -1 (LBW), propofol 2-3 mg kg -1 (LBW) and suxamethonium 1 mg Kg -1 (TBW). When spontaneous respiration ceased, the patient was mask ventilated with 100% oxygen. The tube was lubricated and advanced into the mouth under direct visual guidance to avoid complications, and then, under indirect visual guidance using the GVL monitor. The correct placement of the cuffed tube was verified using a capnograph and a stethoscope. The tube sizes were 7.0 for women and 7.5 for men. Each patient was monitored using an electrocardiogram, non-invasive arterial blood pressure measurement, and pulse oximetry before both tracheal intubation and anaesthesia induction. The basic demographic data and airway characteristics necessary to evaluate the primary outcome and to calculate the EGRI score were registered prior to anaesthesia. Patients with an EGRI score of 7 or higher were scheduled for elective fibre optic flexible bronchoscopic intubation (FFBI), while patients with an EGRI score of less than 7 underwent anaesthesia induction and GVL intubation, according to a predefined algorithm
NEW MATERIAL:A colony stimulating glycoprotein having colony forming stimulating action on mammalian monocytic macrophage based cells and the following physico-chemical properties. Molecular weight; homodimer, consisting of the two same subunits having 70,000-90,000daltons mol.wt. (measured by an SDS-PEGE method). Amino acid sequence of subunits; having an amino acid sequence of 214-238 residues expressed by the formula and Asn at the 122nd and 140th residues with N-glycoside bond part expressed by the formula Asn-X-Thr/Ser (X is amino acid). Isoelectric point; 3.1-3.7. USE:A remedy for leukopenia, immunodeficiency, etc. PREPARATION:For example, human urine is adjusted to pH 8-9 to remove impurities. The resultant urine is subsequently desalted, concentrated, adjusted to pH 6.5-7.5, heat-treated and treated with an anion exchanger. The eluate is then subjected to gel filtration to recover a fraction having >=70,000mol.wt., which is subsequently subjected to high-speed gel filtration and reversed phase high-speed liquid chromatography to afford the aimed colony stimulating factor.
Drug eluting stents have been proven to reduce the restenosis rate in the coronary arteries. Unfortunately drug eluting stents failed to demonstrate superiority over bare stents in the superficial femoral artery. We could show that a non-stent based delivery of Taxan was equal or superior to drug eluting stents in an animal model. This was both true for the coronary arteries and peripheral vessels.

In a prospective blinded trail \>135 patients are randomized either to receive Taxan locally administered with a balloon catheter during balloon angioplasty, or together with contrast media. One group serves as control. There were no limitations due to lesion length. Follow-up angiography will be after 6 months, 12 months and 2 years.
PROBLEM TO BE SOLVED: To provide a liposomal vancomycin preparation.SOLUTION: The present disclosure relates in part to a liposomal vancomycin composition having a low lipid ratio to an agent and a high vancomycin concentration. Further, the present disclosure relates in part to a production method of such a composition. The present invention has an objective to provide a lipid-base vancomycin preparation having low lipid ratio to an agent. In one embodiment, the present invention relates to a liposomal vancomycin comprising a liposome and a vancomycin. In some embodiments, the vancomycin is encapsulated in the liposome. In other embodiments, the vancomycin is in an aqueous medium encapsulated in the liposome, and for example, the aqueous medium is an aqueous gel or a viscous suspension.